As reported in the BiopharmaLife blog, the European Medicines Agency (EMEA) has received word from a European manufacturer that it plans to submit an application for marketing authorization for a stem cell based product. This is a 1st in the EU!
Normally, EMEA is tipped off by client companies approximately 4-6 months before the formal application is filed. Thus, the formal filing should take place late in the year in 2010. As yet, the company's identity is a secret.
Regenerative medicine may be beginning to make its appearance on a commercial stage and to get itself in position for initial use in treatments of cancers and damaged tissues.
Posted by Bruce Lehr May 15th 2010.